SCOPE 2023: Biospecimen Presentation Questions & Insights
Hope Meely, chief clinical officer at Slope, discusses the feedback she received following her SCOPE presentation around biospecimen collection.
In an interview at the 2023 SCOPE conference with ACT Editor-in-Chief, Lisa Henderson, Hope Meely, chief clinical officer at Slope, elaborates on the feedback she received surrounding her conference presentation, "The Hidden Regulatory Risk from Sample Management — What Should You Be Aware of?” This includes the agreement among attendees that the clinical trials industry needs to ensure that biospecimens are managed, especially since they are the driving factors of safety and efficacy data.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How ClinOps Teams Should Evaluate GenAI Tools in Trial Discovery
September 11th 2025
- How Research Sites Balance Funding Cuts and Efficiency Pressures
August 26th 2025
- How Flexible Site Models Can Cut Recruitment Costs and Timelines
August 21st 2025
- Top Questions on Funding Cuts in Clinical Research
August 20th 2025
- Overcoming Budget Barriers to Patient-Centric Trial Models
August 20th 2025